TCON TRACON Pharmaceuticals Inc.

2.08
-0.15  -7%
Previous Close 2.23
Open 2.25
Price To Book 1.67
Market Cap 61919751
Shares 29,840,844
Volume 154,875
Short Ratio 1.92
Av. Daily Volume 88,122

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181058802
  2. 8-K - Current report 181058785
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002314
  4. 8-K - Current report 181001410
  5. 8-K - Current report 18947072

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced December 1, 2017. Presentation of data 2H 2018.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 1b enrollment to be completed 2018.
TRC105 + Avastin
Non-Squamous Cell Lung Cancer
Phase 1 portion of Phase 1/2 trial completed July 2018.
TRC253
Prostate cancer
Phase 2 AVANTE trial initiation announced July 25, 2017. Data due 2H 2019.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with poster presented January 19, 2018 at ASCO GI showing 2/8 partial responses. Full data to be presented at GI ASCO January 17-19, 2019.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 top-line data due December 2018.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2019.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017. Interim analysis due 1Q 2019.
TRC105 (TAPPAS)
Angiosarcoma cancer

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181058802
  2. 8-K - Current report 181058785
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002314
  4. 8-K - Current report 181001410
  5. 8-K - Current report 18947072
  6. 8-K - Current report 18902787
  7. 8-K - Current report 18896943
  8. EFFECT - Notice of Effectiveness 18851220
  9. 424B3 - Prospectus [Rule 424(b)(3)] 18850687
  10. 8-K - Current report 18850106